Please login to the form below

Not currently logged in
Email:
Password:

Greg Perry joins IFPMA as assistant director general

Will move to the global industry body from the Medicines Patent Pool

IFPMA Greg PerryThe International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has appointed Greg Perry to be its new assistant director general.

Perry, who was most recently executive director of the Medicines Patent Pool in Geneva, will move to the global industry body in February.

He has more than 20 years’ leadership and advocacy experience in the public healthcare arena, most recently as executive director of the Medicines Patent Pool, in Geneva.

Prior to his time at the Medicines Patent Pool, which he joined in 2013, Perry spent 14 years as director general of the European Generic Medicines Association.

Thomas Cueni, IFPMA director general, said: “I am very pleased to have someone with such depth of experience and recognised track record joining our leadership. Greg has proven capabilities on a broad range of issues and will help us to cross bridges and reach out to multiple stakeholders equally interested to drive global health progress for the benefit of patients.”

At the IFPMA he will have responsibility for its external outreach and stakeholder engagement on global health topics such as innovation, access, and the international regulatory environment.

Perry said: “I will be joining IFPMA at an exciting time - where the role of the of the private sector as a major player in achieving universal healthcare is now regarded as essential. I have worked in a range of roles in the healthcare arena during the course of my career, but universal health care has been at the core of all of them.”

22nd December 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...

Infographics